Skip to main content
Top

Cardiovascular and renal protection in diabetes: emphasis on SGLT2 inhibitors and GLP-1 receptor agonists

print
PRINT
insite
SEARCH

Saturday June 8, 13:45–15:45. Room B-Hall E, Moscone Center, San Francisco, California

  1. ​​​​​​​Renal effects of GLP-1 receptor agonists: from basic mechanisms to clinical data. Julie A. Lovshin, MD, PhD
  2. Cardiovascular effects of GLP-1 receptor agonists: From basic mechanisms to clinical data. Jens J. Holst, MD, DMSc
  3. Renal effects of SGLT2 Inhibitors: From basic mechanisms to clinical data. David C. Wheeler, MD
  4. Cardiovascular effects of SGLT2 inhibitors:  From basic mechanisms to clinical data. Javed Butler, MD, MPH, MBA


This session links directly to the recent ask the expert videos we produced with Dr Katherine Tuttle [Nephrologist and Endocrinologist], regarding the impact of renal impairment on cardiovascular disease. We should really be discussing "cardio-renal disease" rather than "cardiovascular disease".

– Jay Shubrook, Primary Care Physician

More on this topic

print
PRINT